Mechanism and level of risk are not always obvious (for example, angioedema with an ACE-inhibitor is intolerance not allergy; the reaction may be moderate, but contraindication is absolute) and need not be specified at the time of ADR entry. This evidence concerns the gene ACE and Allergy.